Gena Wang Stock Analyst Profile - Barclays Research Coverage - Stocknear

Gena Wang

Stock Analyst at Barclays

(3.7)
# 2462
Out of 5,474 analysts
266
Total ratings
Success rate
Average return
44 Stocks
Name Action PT Current % Upside Ratings Updated
IONS Ionis Pharmaceutical...
Maintains: Overweight
58 78
64.4 21.12% 12 Sep 3, 2025
CYTK Cytokinetics
Maintains: Overweight
53 71
51.5 37.86% 3 Sep 3, 2025
KOD Kodiak Sciences
Maintains: Underweight
4 7
10.06 -30.42% 9 Aug 14, 2025
RGNX Regenxbio
Maintains: Overweight
50 37
9.89 274.12% 7 Aug 8, 2025
RNA Avidity Biosciences
Maintains: Overweight
59 62
46.62 32.99% 4 Aug 8, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
42 56
53.69 4.3% 17 Aug 6, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
25 21
20.36 3.14% 10 Aug 6, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
40 31
24.47 26.69% 10 Aug 4, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
329 460
482.13 -4.59% 8 Aug 1, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Equal-Weight
10 22
17.64 24.72% 15 Jul 30, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
42 46
58.42 -21.26% 16 Jul 29, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
15 10
5 100% 7 May 16, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
9 5
0.52 861.54% 4 May 14, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
5 4
2.85 40.35% 4 May 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
45 38
6.97 445.19% 2 May 9, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
8 11
8.08 36.14% 10 May 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
40 8
4.97 60.97% 11 Mar 31, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
26 31
5.24 491.6% 6 Feb 28, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
55 26
11.88 118.86% 7 Feb 28, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
435 467
396.48 17.79% 17 Feb 11, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
5 3
2.76 8.7% 9 Dec 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
110 86
55.69 54.43% 13 Oct 4, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
83 81
31.5 157.14% 6 Aug 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
93 94
34.25 174.45% 6 Jan 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
75 71
58.7 20.95% 6 Jul 24, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
145 228
228.74 -0.32% 3 Mar 14, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
7 9
15.23 -40.91% 1 Dec 22, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Equal-Weight
16 25
17.94 39.35% 5 Nov 2, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
60 40
16.7 139.52% 2 May 13, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
32 18
7.65 135.29% 2 May 13, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
72 48
1.4 3328.57% 3 May 11, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
30 7
4.91 42.57% 2 Mar 21, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
208 91
22.47 304.98% 1 Dec 1, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
24 8
7.63 4.85% 1 Nov 17, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
74 79
n/a n/a 1 Aug 6, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Equal-Weight
170 34
n/a n/a 2 Mar 19, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underweight
45 34
n/a n/a 4 May 11, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underweight
21 9
4.71 91.08% 6 Aug 9, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Equal-Weight
74 115
n/a n/a 5 Mar 25, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Equal-Weight
48 75
n/a n/a 1 Dec 10, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Equal-Weight
152 0
n/a n/a 3 Apr 12, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Equal-Weight
n/a
n/a n/a 3 Jan 24, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Underweight
4
n/a n/a 1 Sep 7, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
275
6.83 3926.35% 1 Jan 6, 2017